Plus Therapeutics (NASDAQ:PSTV) Releases Quarterly Earnings Results, Misses Expectations By $0.10 EPS

Posted by Brian Himes on May 16th, 2026

Plus Therapeutics (NASDAQ:PSTV – Get Free Report) posted its quarterly earnings data on Friday. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.95) by ($0.10), FiscalAI reports. The company had revenue of $1.03 million for the quarter.

Plus Therapeutics Price Performance

Shares of PSTV traded down $0.51 during trading hours on Friday, hitting $5.25. The stock had a trading volume of 171,201 shares, compared to its average volume of 199,066. The company’s fifty day moving average is $5.84 and its two-hundred day moving average is $9.42. Plus Therapeutics has a 52 week low of $2.90 and a 52 week high of $23.42. The stock has a market capitalization of $36.02 million, a price-to-earnings ratio of -0.17 and a beta of 1.40.

Analysts Set New Price Targets

Several research firms recently issued reports on PSTV. D. Boral Capital reaffirmed a “hold” rating on shares of Plus Therapeutics in a report on Tuesday, March 31st. Wall Street Zen raised shares of Plus Therapeutics to a “sell” rating in a report on Saturday, April 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Plus Therapeutics in a report on Tuesday, April 21st. Ascendiant Capital Markets decreased their price objective on shares of Plus Therapeutics from $475.00 to $65.00 and set a “buy” rating for the company in a report on Thursday, April 9th. Finally, Lake Street Capital began coverage on shares of Plus Therapeutics in a report on Tuesday, February 3rd. They set a “buy” rating and a $50.00 price objective for the company. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $58.00.

View Our Latest Analysis on PSTV

Institutional Investors Weigh In On Plus Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Susquehanna International Group LLP bought a new stake in Plus Therapeutics during the 3rd quarter worth about $46,000. Jane Street Group LLC bought a new stake in Plus Therapeutics during the 2nd quarter worth about $41,000. State Street Corp grew its holdings in Plus Therapeutics by 37.1% during the 4th quarter. State Street Corp now owns 468,893 shares of the company’s stock worth $240,000 after acquiring an additional 127,000 shares during the last quarter. Scientech Research LLC bought a new stake in Plus Therapeutics during the 3rd quarter worth about $100,000. Finally, XTX Topco Ltd bought a new stake in Plus Therapeutics during the 4th quarter worth about $127,000. Institutional investors own 3.28% of the company’s stock.

Plus Therapeutics Company Profile

(Get Free Report)

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.